Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Cheryle Brandt

Physician Assistant Sioux Falls, SD Physician Assistant

NPI 1457338543 CMS profile 11181092

4950 S Minnesota Ave, Sioux Falls, SD 57108

Open in the dashboard

General payments

$5,553

314 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Cheryle Brandt of Sioux Falls, SD is reported in the CMS Open Payments database as having received $5,553 across 314 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $752 41
2024 General $1,350 64
2023 General $1,424 75
2022 General $1,143 74
2021 General $884 60

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Cheryle Brandt
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Cheryle Brandt were reported at $752. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Cheryle Brandt Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $884 $132 $37–$438 $132
2022 $1,143 $155 $48–$522 $149
2023 $1,424 $167 $52–$557 $160
2024 $1,350 $178 $55–$600 $164
2025 $752 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,570 109 payments
  2. Janssen Biotech, Inc. $704 30 payments
  3. Sun Pharmaceutical Industries Inc. $652 29 payments
  4. Genzyme Corporation $409 18 payments
  5. Novartis Pharmaceuticals Corporation $362 26 payments
  6. Regeneron Healthcare Solutions, Inc. $321 16 payments
  7. Lilly USA, LLC $261 18 payments
  8. UCB, Inc. $238 12 payments
  9. E.R. Squibb & Sons, L.L.C. $221 13 payments
  10. Amgen Inc. $200 10 payments
  11. Other $617 33 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,943 306 payments
  2. Education $610 8 payments
Products named General payments · program years 2021–2025
  1. SKYRIZI Immunology $952 65 payments
  2. DUPIXENT Immunology $653 25 payments
  3. TREMFYA $642 26 payments
  4. ILUMYA $310 19 payments
  5. DUPIXENT Inflammation And Immunology $268 14 payments
  6. TALTZ $261 18 payments
  7. HUMIRA $256 17 payments
  8. SOTYKTU $221 13 payments
  9. SKYRIZI Immunology $206 14 payments
  10. RINVOQ $205 15 payments
  11. Other $1,902 117 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

590

Median for Physician Assistant: 241

Drug cost

$12,099

Median for Physician Assistant: $4,110

Branded share of claims

4.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ketoconazole Generic 161 $4,074
Clobetasol Propionate Generic 33 $2,734
Triamcinolone Acetonide Generic 122 $1,005
Metronidazole Generic 19 $948
Dutasteride Generic 27 $781
Doxycycline Hyclate Generic 48 $695
Clindamycin Phosphate Generic 14 $517
Fluocinonide Generic 13 $470
Valacyclovir Valacyclovir Hcl Brand 27 $237
Mupirocin Generic 22 $146

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$72,548

Of which drugs: $957

Medicare patients

486

Average age 74

Services billed

1,953

292 women, 194 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 59%
Arthritis 37%
Ischemic heart disease 20%
Diabetes 17%
Osteoporosis 16%
Cancer 14%
Atrial fibrillation 13%
Chronic kidney disease 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 24 44 $27

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $315
$315 — —
DUPIXENT
  • GENZYME CORPORATION $124
  • SANOFI-AVENTIS U.S. LLC $92
  • Regeneron Healthcare Solutions, Inc. $69
$285 — —
Bimzelx
  • UCB, Inc. $113
$113 — —
Otezla
  • Amgen Inc. $105
$105 — —
TREMFYA
  • Janssen Biotech, Inc. $97
$97 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

314 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in South Dakota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record